Vertex Pharmaceuticals stock tracks kidney pipeline progress
Published on 09/24/2026 at 19:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Vertex Pharmaceuticals stock was trading at USD 520.96 on Nasdaq on September 24, 2026 at 1:49 p.m. ET, up 0.89 percent from the previous close and 7.01 percent below its 52-week high of USD 560.25. The immediate catalyst is the company's September 22, 2026 update on its inaxaplin kidney program.
Inaxaplin delivers a measurable result
According to Vertex Pharmaceuticals, the Phase 2b AMPLIFIED study produced a 42.7 percent reduction in urine albumin to creatinine ratio at Week 13 for patients with APOL1-mediated kidney disease and modest proteinuria. The type 2 diabetes cohort posted a smaller 17.3 percent reduction.
The study included 22 patients in the modest-proteinuria cohort and 17 patients in the diabetes cohort. Vertex said the treatment produced no serious adverse events related to inaxaplin, while headache occurred in 7.3 percent of participants.
Revenue growth offsets the EPS miss
Vertex's latest reported quarter, Q2 2026, generated USD 3.33 billion in revenue, up 12.5 percent from the prior-year quarter and above the USD 3.23 billion consensus estimate, according to MarketBeat. Adjusted EPS was USD 4.73, narrowly below the USD 4.74 consensus.
That contrast matters for the pipeline story. Revenue growth supplies operating support, while inaxaplin must now convert a promising mid-stage signal into evidence from the pivotal AMPLITUDE program. Vertex expects interim analysis results in early 2027, a date that gives the kidney franchise a defined clinical checkpoint.
Vertex stock stays below its yearly high
Vertex Pharmaceuticals had a market capitalization of USD 132,221,846,712 as of September 24, 2026. The stock's USD 520.96 intraday price remained above its 52-week low of USD 377.02 and below the USD 560.25 high, leaving the clinical data and future trial execution as the main company-specific valuation variables.
Vertex Pharmaceuticals at a glance
- Company: Vertex Pharmaceuticals Incorporated
- Ticker: VRTX
- Trading venue: Nasdaq
- Price: USD 520.96, September 24, 2026 at 1:49 p.m. ET
- Market capitalization: USD 132,221,846,712 as of September 24, 2026
- 52-week range: USD 377.02-560.25
- Sector / Industry: Healthcare / Biotechnology
- Index membership: Nasdaq-100
